Blue Cross NC Adds New Biosimilars for Humira (adalimumab) to Commercial Formularies
July 07, 2023
On 7/1/2023, new biosimilars for Humira (adalimumab) will be added to Blue Cross and Blue Shield of North Carolina commercial formularies. There will be no changes in coverage of Humira products. Coverage of specific biosimilars will vary by formulary, but may include Amjevita, Cyltezo, or Hadlima. You can identify preferred products on MyPrime.com after 7/1/2023. Because there are no clinically meaningful differences between Humira and the biosimilar adalimumab products, patients are not expected to experience a change in the safety or effectiveness of their treatment if members utilize covered adalimumab biosimilars. Refer to the FDA resource (PDF) for further information.